Searching for a cure, Improving lives

Steering Committee

The DMD Registry Steering Committee 

A Steering Committee is made up of at least five senior health professionals and researchers who are responsible for authorising and approving all access to the Registry by any researcher and/or health professional for the purposes of a specific research project or for the purposes of a specific course of treatment.

 

Members of the Steering Committee:

Dr Stephen Abbs (molecular geneticist) [Chair]

Director of Genetics Laboratories

Cambridge University Hospitals NHS Foundation Trust

Addenbrooke’s Hospital

 

Dr Emma Ashton (molecular geneticist)

Clinical Scientist

North East Thames Regional Genetics Service

Great Ormond Street Hospital NHS Trust

 

Therese Bradley (molecular geneticist)

Prinicipal Clinical Scientist

West of Scotland Genetic Services

 

Prof Kate Bushby (clinician)

Neuromuscular Genetics

Institute of Genetic Medicines

International Centre for Life

Nick Catlin (parent representative)

Co-founder of Action Duchenne

 

Mark Chapman (patient representative)

 

Dr Anne-Marie Childs (clinician)

Consultant Paediatric Neurologist

Leeds General Infirmary

 

Prof. Hanns Lochmuller (TREAT-NMD Alliance Neuromuscular Network)

Experimental Myology

Newcastle University

International Centre for Life

 

Dr Jo McCauley (molecular geneticist)

(Formerly of Molecular Genetic Laboratory at Guy’s & St Thomas’ Hospital)

 

Dr. Karen Naismith (clinician)

Consultant Paediatric

Ninewells Hospital & Medical School

 

Dr. Ros Quinlivan (clinician)

The National Hospital for Neurology and Neurosurgery

 

Angela Stringer (DMD Registry Curator)

 

 

Donate

Support Action Duchenne with a monthly or one off donation

Donate

Events

View our events

View All Events

Registry

Join the DMD registry for access to clinical trials

Register

Summit presents data from Phase 1 clinical programme of lead utrophin modulator, ezutromid

June 22nd, 2017

Summit Therapeutics has today announced the presentation of clinical data from two Phase 1 clinical trials

Tell me more

What Raxone being given approval through the EAMS scheme means for the Duchenne community

June 22nd, 2017

  Over a number of years we have worked closely with Santhera Pharmaceuticals and other

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne